| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 7, 2021 4:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 7, 2021 4:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
Save time and jump to the most important pieces.
4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
GREENWICH, Conn., June 11, 2025 /PRNewswire/ -- Blue Water Acquisition Corp. III (the "Company") (NASDAQ:BLUWU), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Chairman and Chief Executive Officer Joseph Hernandez, today announced the closing of its upsized initial public offering of 25,300,000 units, which includes 3,300,000 units issued pursuant to the full exercise by the underwriters of their over-allotment option, at an offering price of $10.00 per unit, resulting in gross proceeds of $253,000,000. The Company'
GREENWICH, Conn., June 10, 2025 /PRNewswire/ -- Blue Water Acquisition Corp. III (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Chairman and Chief Executive Officer Joseph Hernandez, today announced the upsized pricing of its initial public offering of 22,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant will entitle the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. The units are expected to trade on The Nasdaq Global Market ("Nasdaq")under the ticker symbo
GREENWICH, Conn., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ:BLUW), a special purpose acquisition company ("Blue Water"), today announced that its stockholders have voted to approve the proposed business combination (the "Business Combination") with Clarus Therapeutics, Inc., a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women ("Clarus") at its special meeting of stockholders (the "Special Meeting") held today, August 27, 2021. Holders of approximately 73.95% of Blue Water's issued and outstanding shares cast votes at the Special Meeting. Approximately 69.57% o
EFFECT - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
424B3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
S-1 - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
SC 13G/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)
SC 13G - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)
SC 13D - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)